Literature DB >> 10484503

Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats.

G F Torelli1, M M Meguid, L L Moldawer, C K Edwards, H J Kim, J L Carter, A Laviano, F Rossi Fanelli.   

Abstract

With progression of tumor growth, rats demonstrate anorexia and reduced food intake, a function of meal number and meal size. Tumor necrosis factor-alpha (TNF-alpha), a recognized anorectic agent, reacts with two different receptors (type I: 55 kDa; type II: 75 kDa). We used a dimeric, pegylated 55-kDa TNF receptor construct to test its effects on food intake, meal number, and meal size, which were continuously measured with a rat eater meter in 16 Fischer 344 male rats injected with 10(6) viable methylcholanthrene cells. When anorexia developed, rats received a subcutaneous injection of either 0.25 mg/kg body wt of soluble TNF receptor construct (study) or vehicle (tumor-bearing control). Before TNF inhibitor injection, no differences were observed in food intake, meal number, or meal size between the two groups. After the TNF inhibitor injection, study vs. control rats significantly improved food intake as a result of an increase in meal number and meal size. Rats also showed a significant improvement in body weight. These data suggest that TNF-alpha, in addition to other cytokines, contributes to the anorexia of tumor growth, probably mediated via the hypothalamus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484503     DOI: 10.1152/ajpregu.1999.277.3.R850

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

Review 1.  Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update.

Authors:  M W Davis; U Feige; A M Bendele; S W Martin; C K Edwards
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  The cancer anorexia/weight loss syndrome: therapeutic challenges.

Authors:  Karin F Giordano; Aminah Jatoi
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

Review 3.  Anorexia in cancer: role of feeding-regulatory peptides.

Authors:  Simona Perboni; Akio Inui
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 4.  Cancer cachexia, mechanism and treatment.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Hisahiro Matsubara; Kazuaki Takabe
Journal:  World J Gastrointest Oncol       Date:  2015-04-15

5.  A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).

Authors:  Aminah Jatoi; Howard L Ritter; Amylou Dueck; Phuong L Nguyen; Daniel A Nikcevich; Ronnie F Luyun; Bassam I Mattar; Charles L Loprinzi
Journal:  Lung Cancer       Date:  2009-08-08       Impact factor: 5.705

6.  Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer.

Authors:  Pei-Hung Chang; Cheng-Hsu Wang; Eric Yen-Chao Chen; Shih-Wei Yang; Wen-Chi Chou; Jason Chia-Hsun Hsieh; Feng-Che Kuan; Kun-Yun Yeh
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

7.  Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial.

Authors:  Aminah Jatoi; James Egner; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; Shaker R Dakhil; James A Mailliard; George G Klee; James E Krook
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 8.  Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.

Authors:  Yuji Miyamoto; Diana L Hanna; Wu Zhang; Hideo Baba; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2016-06-23       Impact factor: 12.531

9.  Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation.

Authors:  Leah M Pyter; Vanessa Pineros; Jerome A Galang; Martha K McClintock; Brian J Prendergast
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

10.  A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.

Authors:  Aminah Jatoi; James R Jett; Jeff Sloan; Paul Novotny; Joyce Ford; Uma Prabhakar; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2004-09-15       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.